Olympus America Inc. and LabOne, Inc. Sign Agreement for High-Production AU5400TM Chemistry Immuno AnalyzersMelville, NY - The Diagnostic Systems Group of Olympus America Inc. and LabOne, Inc. have signed an agreement whereby LabOne will use Olympus equipment, primarily Olympus AU5400TM automated chemistry-immuno analyzers, for toxicology and clinical chemistry testing.
The transaction is expected to facilitate reductions in operating costs and improve efficiency in toxicology and chemistry testing at LabOne. Specific terms of the multi-year contract were not disclosed, yet company officials said the agreement encompasses the installation of multiple Olympus analyzers and the use of Olympus reagents, consumables and parts at LabOne's Lenexa, KS facility.
"We have benefited from our relationship with Olympus for several years," said W. Thomas Grant II, Chairman, President and CEO of LabOne. "The company's innovative design, sophisticated automation, quality products and services have significantly contributed to our operating efficiency and productive capacity. With the capabilities of the new AU5400 we expect to achieve further economies of scale, and the higher throughput allows us to use fewer analyzers and re-allocate personnel to other areas of the laboratory. This is an obvious benefit to a lab that runs more than 30,000 samples per day."
Designed to meet the needs of high volume commercial and core laboratories, the Olympus AU5400TM automates and consolidates chemistry-immuno testing with up to 147 on-board chemistries and throughput up to 6,600 tests per hour. The system requires less maintenance and consumes less reagent than other modular high volume analyzers. In the LabOne environment, it is expected that operators will likely re-allocate 75% of the time previously spent on instrument maintenance to other vital functions and reagent consumption will be reduced by 50%.
"We are pleased to continue our long-standing relationship with LabOne," said Stephen Wasserman, Group Vice President, Diagnostic Systems Group of Olympus. "The new line of Olympus analyzers and reagents are designed to optimize laboratory operations. Our goal has always been focused on providing high-quality, cost-effective diagnostic testing solutions for hospital and commercial laboratories."
About LabOne, Inc.
LabOne is a national laboratory testing and information service provider with three divisions: risk assessment services, healthcare and substance abuse testing. The risk assessment division, with its ExamOne and SBSI subsidiaries, provides proprietary information technologies CaseView and LabOne NETTM, and CaseOne case management service, to life and health insurance companies. These services include laboratory test results, paramedical examinations, attending physician statements, motor vehicle reports, background inspections and personal history interviews.
LabOne's healthcare division provides medical diagnostic testing and related services to physicians and managed care organizations, and to benefit providers through its unique Lab Card® employee benefit program. The healthcare division's disease management reporting is specifically designed to provide managed care clients with HEDIS data necessary for their NCQA accreditation. The company's substance abuse testing division provides drug testing services to Fortune 1000 employers and markets InterceptTM, the oral fluid drug test, in the workplace drug testing market. The company's web site is located at www.LabOne.com.
About Olympus Diagnostic Systems Group
Since 1981, Olympus Diagnostic Systems Group has provided innovative solutions that meet the high productivity demands of hospitals, integrated health delivery networks, blood banks, reference labs and pharmaceutical labs. Offering the broadest standardized line of random access, chemistry-immuno systems, Olympus' high performance solutions save laboratories time, maximize productivity and deliver fast, reliable results.
Annually, over 1 billion clinical chemistry tests - about one in four - are performed on Olympus analyzers in the U.S. And more than 90% of North America's blood donor centers use Olympus blood analyzer systems for blood typing. Olympus Diagnostic Systems Group also offers rapid response technical support nationwide through Olympus Technical Services. Service and support is available to customers seven days a week, 24 hours a day, by calling 1-800-223-0130. From telephone troubleshooting and remote modem diagnostics...to on-site service for hardware, software and application support...to on-site operator training, as well as training and field support at Olympus' Irving, Texas facility...Olympus Diagnostic Systems Group provides comprehensive customer solutions to ensure maximum system uptime with reliable results.
About Olympus America Inc.
Based in Melville, NY, Olympus America Inc. distributes a wide range of products that leverage its core expertise in optics and digital information technology for the consumer, scientific, healthcare, and commercial markets. These products include film and digital cameras, microcassettes and digital voice recorders, binoculars, film scanners, personal photo printers, medical endoscopes, biological and metallurgical microscopes and measuring instruments, clinical diagnostic analyzers, and other high-technology products.
Olympus America Inc. is responsible for sales, marketing, and distribution in the U.S., Canada, Mexico, the Caribbean, and Central and South America. Olympus America Inc. is a subsidiary of Olympus Optical Co., Ltd. with worldwide revenues of $4.2 billion for the fiscal year ending March 2001.
For additional information about the Olympus AU product line, and other services, please call the Olympus Diagnostic Systems Group at 1-800-223-0125.
This press release contains "forward-looking statements," including general statements of cost reductions and operating efficiencies related to the utilization of new equipment, and statements of assumptions underlying such statements. Forward-looking statements involve known and unknown risks and uncertainties. Many factors could cause actual results to differ materially from those that may be expressed or implied in such forward-looking statements, including, but not limited to, the ability to integrate the new equipment into the testing performed by LabOne and the equipment's performance as expected, the volume and pricing of laboratory tests performed by LabOne, competition, the extent of market acceptance of the company's testing services in the healthcare and substance abuse testing industries, general economic conditions and other factors detailed from time to time in the company's reports and registration statements filed with the Securities and Exchange Commission.